This episode explores how chronic myeloid leukemia has been transformed by imatinib and other TKIs, while also showing why major clinical challenges remain for the patients who do not respond well or want to stop therapy. Host Scientific Editor Dr Charles de Bock talks with Dr. Ilaria Pagani about her recent HemaSphere paper on mitochondrial DNA mutations, oxidative phosphorylation, and treatment response in CML, and why mitochondria may be an overlooked source of biomarkers and new targets. We discuss the biology of relapse, why some patients can achieve treatment-free remission, and how mitochondrial metabolism may help explain differences between poor responders and super responders. The conversation also touches on patient advocacy, quality of life, and the need for more collaborative, metabolism-focused research.

Read the article in full, open access: https://hsphere.pub/448

You've read the paper, now hear the story.